ADE17 Antibody

What detection methods are most effective for measuring ADAM17 in clinical samples?

ADAM17 can be reliably detected in both serum and ascites fluid of patients using sandwich ELISA, with concentration levels typically ranging between 1500-3500 pg/mL in cancer cell supernatants. For optimal detection in patient samples:

• Use a calibrated sandwich ELISA with appropriate standards

• Process serum samples within 2 hours of collection to prevent degradation

• Compare paired samples when possible (e.g., serum and ascites)

• Include age-matched controls negative for ADAM17-associated diseases

Research shows ADAM17 levels in ascites samples are approximately 2.5 times higher than corresponding serum samples from the same patient, with significant individual variation (e.g., 3859 pg/mL in serum vs. 4246 pg/mL in ascites for one patient; 85 pg/mL in serum vs. 177 pg/mL in ascites for another) .

How should researchers interpret ADAM17 expression differences between serum and tissue samples?

Interpretation requires consideration of several factors:

• ADAM17 is released into circulation from solid tumors and can be detected in patient serum

• Higher ADAM17 concentrations are associated with early FIGO stages in ovarian cancer

• Detection in serum was previously only described for inflammatory conditions, not gynecological malignancies

• Western blot quantification should include appropriate loading controls

When comparing tissue and serum expression, researchers should normalize measurements and consider that expression patterns may reflect disease stage rather than simply correlating with tumor burden .

What controls are essential when studying ADAM17 antibody binding specificity?

Proper controls are critical for binding specificity experiments:

• Include protein A-Sepharose beads alone as negative control

• Use isotype-matched control antibodies to rule out non-specific binding

• Test binding of antibodies to both the full extracellular domain (ECD) and individual domains (e.g., D+C)

• Validate results across multiple experimental approaches (e.g., pull-down assays plus functional tests)

When evaluating anti-ADAM17 monoclonal antibodies, researchers should test their effects on protein-protein interactions separately from their effects on enzymatic activity .

How can researchers effectively design experiments to study ADAM17-mediated proteolysis?

For robust proteolysis experiments:

• Include positive controls (e.g., PMA-induced cleavage)

• Use specific inhibitors like TAPI to confirm ADAM17 involvement

• Analyze both cell lysates and culture supernatants to capture released fragments

• Test multiple antibodies targeting different domains to dissect functional requirements

• Perform time-course experiments to capture cleavage kinetics

When studying p75 cleavage by ADAM17, researchers should probe for both released extracellular domain in media and retained fragments in cell lysates using domain-specific antibodies .

How do different anti-ADAM17 antibodies affect protein-protein interactions versus enzymatic activity?

Different antibodies exhibit distinct functional effects:

These differential effects suggest the binding interface between ADAM17 and substrate complexes differs from the catalytic site, allowing for selective targeting of specific functions .

What methodological challenges exist when studying ADAM17's role in neuronal regeneration?

Key methodological considerations include:

• Neurite outgrowth assays require careful design to distinguish individual neurites

• Primary neurons (e.g., E18 rat hippocampus) provide more reliable results than cell lines

• Quantification should include both neurite length and branching parameters

• Substrate-adhered myelin-associated glycoprotein (MAG) may better mimic in vivo conditions

• Individual fiber length distribution charts increase data reliability

Researchers should validate findings across multiple experimental systems and use appropriate statistical analyses with clearly reported sample sizes and biological replicates .

How should researchers address discrepancies in ADAM17 binding studies?

When encountering binding discrepancies:

• Consider structural constraints - full ECD may adopt conformations different from isolated domains

• Verify protein folding and quality through multiple purification batches

• Test binding under various conditions (pH, salt concentration, temperature)

• Use multiple detection methods (ELISA, SPR, co-IP) to confirm interactions

For example, research shows discrepancies in binding between ADAM17-ECD versus the D+C domains to p75, suggesting the D+C domains in the ECD may be insufficient to maintain interaction with p75 under certain conditions .

How can western blot data for ADAM17 cleavage products be properly quantified?

For reliable western blot quantification:

• Use triplicate determinations from at least two independent experiments

• Include appropriate loading controls (e.g., GAPDH for cell lysates)

• Normalize band intensities to controls

• Present both representative blots and quantitative analyses

• Report statistical methods and significance

When analyzing p75 cleavage by ADAM17, researchers should centrifuge samples before performing western blots, with supernatants (containing released p75) resolved on upper gels and pellets (containing cell-associated GAPDH) on lower gels .

What considerations are important when evaluating ADAM17 as a biomarker?

For biomarker evaluation:

• Compare against established markers (e.g., CA-125 for ovarian cancer)

• Establish appropriate cutoff values through ROC curve analysis

• Correlate with clinicopathological parameters

• Consider combining with other markers for improved sensitivity/specificity

Research shows ADAM17 levels are significantly increased in ovarian cancer patients compared to age-matched controls (p < 0.0001), with early FIGO I/II stages associated with higher ADAM17 concentrations (p = 0.007) .

How should researchers design studies to evaluate ADAM17 antibodies for therapeutic applications?

Therapeutic evaluation requires:

• In vitro functional assays (e.g., neurite outgrowth inhibition reversal)

• Comparison with established therapeutic approaches

• Dose-response studies to determine optimal concentrations

• Assessment of potential off-target effects

• Evaluation of antibody stability and half-life

Anti-ADAM17 monoclonal antibodies (mAbs) targeting the protease's active site show potential for promoting axon regeneration across various human pathological conditions, though high-resolution structural data of the protein complex is needed to determine exact catalytic mechanisms .

What are the most promising approaches for studying ADAM17 in early cancer detection?

Promising research avenues include:

• Combined biomarker panels incorporating ADAM17 with established markers

• Longitudinal studies tracking ADAM17 levels throughout disease progression

• Investigation of ADAM17 in minimally invasive liquid biopsies

• Correlation of ADAM17 activity with treatment response

• Development of point-of-care testing methods

ADAM17 appears particularly promising for detecting early-stage ovarian cancer, especially in cases where CA-125 results would be negative .

What technological advances would benefit ADAM17 antibody research?

Key technological needs include:

• High-resolution structural determination of ADAM17-antibody complexes

• Development of more specific inhibitors targeting distinct domains

• Improved imaging methods for visualizing ADAM17 activity in live cells

• More sensitive detection methods for low-abundance cleaved products

• Standardized protocols for comparing results across laboratories